gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BDSXHealthcareMedical Labs

Biodesix, Inc. Common Stock (BDSX)

$21.44+1.85%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$21.44▲ 238.17% in range
Nov 3, 2025Low $5.46 · High $30.60Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Biodesix closed at $21.44 on Nov 4, up 1.85%, 29.9% below its 52-week closing high. Volume of 115.1K shares was 1.55× its 20-day average (above normal).

Split-adjusted performance: -23.3% over one month, +42.9% over six months, +238.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $26.86M, up 34.2% from a year earlier, with a net margin of -27.1%.

Short interest was 209.5K shares at the Oct 15 settlement, up 3.8% from the prior report (4.7% of float, 2.4 days to cover).

Market cap$226.2M10.6M shares
Revenue · quarter$26.9M+34.2% YoY
Diluted EPS$-0.71—
P/E · TTM—P/S 2.2×
Net margin-27.1%Gross 82.1%
Dividend yieldNone
52-week range5.46 – 30.60−29.9% from high
Volume115.1K1.55× 20-day avg
Volatility · 60d76.8%Annualised
Short % of float4.7%2.4 days to cover
Net cash-$16.8MCash $30.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −6.2%1M −23.3%3M −3.0%6M +42.9%YTD +215.3%1Y +238.2%3Y −27.6%5Y −85.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum64
Revenue growth72
Net margin33
Value (low P/E)—
Size26

Industry medians: 6-month return +36.5%, revenue growth +25.0%, net margin −4.0%, P/E 32.5×.

Short interest

Details →
Shares short209.5K+3.8% vs prior
Days to cover2.4Settled Oct 15
% of float4.7%
Short vol. 10d37.8%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BDSXBiodesix$21.44+1.85%+42.9%+34.2%−27.1%—$226.2M
XGNExagen$8.53+2.30%+176.1%+15.9%−16.0%—$206.7MCompare
FLGTFulgent Genetics$19.86+2.50%+33.1%+4.4%−34.6%—$546.3MCompare
SERASera Prognostics$2.06+6.61%+13.7%+76.5%−30463.3%—$81.2MCompare
CSTLCastle Biosciences$35.94+2.28%+45.2%+20.1%−2.0%—$1.10BCompare
FRNMFreenome$11.23−2.09%————$1.21BCompare
LMRILumexa Imaging Holdings$12.68+13.01%+23.3%—1.0%—$1.22BCompare
PSNLPersonalis$15.76+0.06%+159.6%+30.0%−141.7%—$1.68BCompare
FTREFortrea Holdings$20.87−0.37%+33.5%−1.4%0.1%—$2.01BCompare

News about Biodesix

All news →
Biodesix to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · 20h agoNeutralAll You Need to Know About Biodesix (BDSX) Rating Upgrade to BuyZacks Investment Research · 6d ago▲ PositiveBiodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging BiomarkersGlobeNewswire Inc. · Oct 19, 2026▲ PositiveBiodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026GlobeNewswire Inc. · Oct 13, 2026▲ PositiveBiodesix to Report Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswire Inc. · Jul 22, 2026Neutral

Quick answers

What does Biodesix do?
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers.
What is BDSX's market cap?
$226.22M, based on the Nov 4 close of $21.44.
Does Biodesix pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BDSX is sold short?
209.5K shares, 4.7% of float, as of Oct 15, 2026.
What sector is BDSX in?
Healthcare, in the Medical Labs industry.

About Biodesix

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

HQ: Louisville, CO334 employeesListed Oct 28, 2020biodesix.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology